Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | BMX | P51813 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | FRK | P42685 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333432 | 1.00 | GSK3B (0.38) | GSK3BMAPK11MAPK14MAPK1GRM5 | |
| SCHEMBL29333552 | 0.87 | MAPK1 (0.40) | MAPK1CCNCCDK8BTKEGFR | |
| SCHEMBL29333580 | 0.86 | CCNC (0.36) | MAPK1CCNCCDK8BTKEGFR | |
| SCHEMBL31008550 | 0.86 | HCRTR1 (0.36) | GSK3BMAPK1GRM5CCNCCDK8 | |
| SCHEMBL29333448 | 0.86 | HCRTR1 (0.36) | GSK3BMAPK1GRM5CCNCCDK8 | |
| SCHEMBL29333420 | 0.85 | CCNC (0.37) | MAPK1CCNCCDK8BTKEGFR | |
| SCHEMBL31008646 | 0.85 | CDC7 (0.39) | GSK3BMAPK1CCNCCDK8BTK | |
| SCHEMBL29333427 | 0.85 | CDC7 (0.39) | GSK3BMAPK1CCNCCDK8BTK | |
| SCHEMBL31008607 | 0.85 | CCNC (0.37) | MAPK1CCNCCDK8BTKEGFR | |
| SCHEMBL31008609 | 0.85 | CCNC (0.36) | MAPK1GRM5CCNCCDK8EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | GSK3B 495/4885MAPK11 1578/4885MAPK14 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.